摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Methyl-2-aethyl-thionaphthen | 89325-29-1

中文名称
——
中文别名
——
英文名称
3-Methyl-2-aethyl-thionaphthen
英文别名
Methylethylbenzothiophene;2-ethyl-3-methyl-1-benzothiophene
3-Methyl-2-aethyl-thionaphthen化学式
CAS
89325-29-1
化学式
C11H12S
mdl
——
分子量
176.282
InChiKey
OBUFELGZMPHZPR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    28.2
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • [EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES PERMETTANT DE MODULER LE CFTR
    申请人:PROTEOSTASIS THERAPEUTICS INC
    公开号:WO2017062581A1
    公开(公告)日:2017-04-13
    The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    本公开涉及揭示的化合物,可以调节,例如,解决CFTR活性细胞处理中的潜在缺陷。
  • FUSED HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
    申请人:Leonard Kristi Anne
    公开号:US20120129872A1
    公开(公告)日:2012-05-24
    This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables A, Q, J, R 1 , R 3 , and R 5 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.
    该发明涉及噻唑I及其治疗和预防用途,其中变量A、Q、J、R1、R3和R5在规范中有定义。治疗和/或预防的疾病包括类风湿性关节炎。
  • Novel piperidine derivative
    申请人:Ban Hitoshi
    公开号:US20070078120A1
    公开(公告)日:2007-04-05
    The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0-4, provided 3≦m+n≦8; X is nitrogen atom or a group of the formula: C—R 15 ; Y is a substituted or unsubstituted aromatic group, etc.; R 15 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.
    本发明提供了以下式(1)的化合物:其中m,n和p分别是0-4的整数,满足3≦m+n≦8;X是氮原子或式:C—R15的基团;Y是取代或未取代的芳香基团等;R15,R1,R2,R3,R4,R5,R6和R7是氢原子,取代或未取代的烷基等;Z是氢原子,基等,或其前药,或其药学上可接受的盐,具有增强LDL受体表达的作用,并且可用作治疗高脂血症,动脉粥样硬化等药物。
  • 4-Amino-5-Cyanopyrimidine Derivatives
    申请人:Kato Masaya
    公开号:US20080182854A1
    公开(公告)日:2008-07-31
    The present invention provides 4-amino-5-cyanopyrimidine derivatives of the formula: wherein R 1 , R 2 and R 3 are defined herein, or pharmaceutically acceptable salts thereof, having a safe and potent adenosine A2a receptor agonistic activity; and also provides an adenosine A2a receptor agonist, an intraocular pressure reducing agent, or a medicine for treating glaucoma, etc., which comprises the compound as an active ingredient.
    本发明提供了式子如下的4-基-5-氰基嘧啶生物:其中R1、R2和R3如本文所定义,或其药学上可接受的盐,具有安全有效的腺苷A2a受体激动活性;同时还提供了一种腺苷A2a受体激动剂、降眼压剂或治疗青光眼等药物,其包含该化合物作为活性成分。
  • HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS
    申请人:BATTISTA Kathleen
    公开号:US20090124614A1
    公开(公告)日:2009-05-14
    The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    本发明涉及一种新型的羟基烷基取代的1,3,8-三氮杂螺[4.5]癸酮生物,其通式如下:其中所有变量均如本文所定义,可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和症状。更具体地,本发明的化合物可用于治疗焦虑、抑郁、惊恐、痴呆、躁狂、双相情感障碍、物质滥用、神经病性疼痛、急性疼痛、慢性疼痛、偏头痛、哮喘、咳嗽、精神病、精神分裂症、癫痫、高血压、肥胖症、进食障碍、渴望、糖尿病、心律失常、肠易激综合征、克罗恩病、尿失禁、肾上腺疾病、注意力缺陷障碍(ADD)、注意力缺陷多动障碍(ADHD)、阿尔茨海默病,以改善认知或记忆,并用于情绪稳定。
查看更多

同类化合物

齐留通钠 齐留通相关物质A 齐留通亚砜 齐留通-d4 齐留通 雷洛昔芬杂质 邻联甲苯胺砜 试剂4,8-Bis(3,5-dioctyl-2-thienyl)-2,6-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[1,2-b:4,5-b']dithiophene 试剂1,1'-[4,8-Bis[4-(2-ethylhexyl)-3,5-difluorophenyl]benzo[1,2-b:4,5-b']dithiophene-2,6-diyl]bis[1,1,1-trimethylstannane] 苯并噻吩-7-醇 苯并噻吩-4-硼酸频哪醇酯 苯并噻吩-3-羧酸甲酯 苯并噻吩-3-硼酸 苯并噻吩-2-羰酰氯 苯并噻吩-2-羧酸肼 苯并噻吩-2-羧酸 苯并噻吩-2-硼酸 苯并噻吩-2-氨基甲酸叔丁酯 苯并噻吩 苯并[c]噻吩 苯并[b]噻吩-7-胺 苯并[b]噻吩-7-羧酸乙酯 苯并[b]噻吩-7-甲醛 苯并[b]噻吩-7-甲腈 苯并[b]噻吩-6-醇 苯并[b]噻吩-6-胺 苯并[b]噻吩-6-羧酸乙酯 苯并[b]噻吩-6-羧酸 苯并[b]噻吩-6-甲腈 苯并[b]噻吩-5-甲腈,2-甲酰基- 苯并[b]噻吩-5-甲磺酰氯 苯并[b]噻吩-4-羧酸甲酯 苯并[b]噻吩-4-羧酸 苯并[b]噻吩-4-甲醛 苯并[b]噻吩-4-甲腈 苯并[b]噻吩-4-基甲醇 苯并[b]噻吩-3-胺盐酸盐 苯并[b]噻吩-3-胺 苯并[b]噻吩-3-羧酸-(2-二烯丙基氨基乙酯) 苯并[b]噻吩-3-硼酸频哪酯 苯并[b]噻吩-3-甲醛肟 苯并[b]噻吩-3-甲酰胺 苯并[b]噻吩-3-基乙酸酯 苯并[b]噻吩-3-乙酸 苯并[b]噻吩-3-乙酰氯 苯并[b]噻吩-3-乙腈 苯并[b]噻吩-2-胺盐酸盐 苯并[b]噻吩-2-羧酸6-氨基-3-氯-甲酯 苯并[b]噻吩-2-羧酸,5-氯-3-(1-甲基乙氧基)- 苯并[b]噻吩-2-羧酸,3-羟基-5-甲氧基-,甲基酯